In the advent of the COVID-19 outbreak in Korea, Myongji Hospital adopted a dual-track healthcare system to provide continuity of care for its patients while managing referred COVID-19 patients simultaneously. We assessed infection control efforts by comparing data collected over 20 weeks during a pandemic under a dual-track healthcare system. A decline in non-COVID-19 patients visiting the emergency department by 37.6% (P<0.01) was observed since admitting COVID-19 cases. However, patients with acute myocardial infarction (AMI), stroke, severe trauma and acute appendicitis presenting for emergency care did not decrease. Door-to-balloon time for AMI improved significantly while door-to-needle time in stroke management remained steady. Simultaneously, time-sensitive care involving other clinical services, including patients requiring chemotherapy, radiation therapy and haemodialysis did not change. During this presentation, Dr. Lee will discuss the keys to successfully operating a dual-track healthcare system amidst ongoing COVID-19 pandemic.                                                                                                                                                                                                             Biography:

Dr. Wangjun Lee is one of the most influential person in the Korean healthcare sector. He is chairman and CEO of Myongji Medical Foundation, and running two more acute care hospitals and 3 long-term care(LTC) facilities. Also, he is CEO of Korea’s most influential healthcare news & publishing company, ‘The Korean Doctors’ Weekly’, founded in 1992. He is one of the leading NGO activists in the medical aid area for migrant workers in Korea, and now serves as vice chairman of the Migrant Health Association in Korea. As an Executive Chairman of international affairs of the Korean Hospital Association, he is in charge of general secretary of the Korea Healthcare Congress, which is the top healthcare related annual congress in Asia. He is also a CEO and Chairman of very venturous biotech company ‘CancerROP’ that is listed in KOSDAQ market, along with a cell therapy company ‘MJ CellBio’. Dr. Lee graduated from Seoul National University, College of Medicine. He achieved board of surgery in Seoul National University Hospital. He was awarded a Ph.D. degree from the same University.